Table 2 Outcomes of included patients who received more than three intravitreal conbercept injections for AMD and DME.
Total | AMD | DME | |
|---|---|---|---|
Total number of injections | 392 | 314 | 78 |
Injection/Non-injection (p) | Injection/Non-injection (p) | Injection/Non-injection (p) | |
Average IOP (mmHg) | 15.5 ± 2.9/15.5 ± 3.0 (0.887) | 15.5 ± 2.9/15.4 ± 3.0 (0.641) | 15.7 ± 2.8/15.9 ± 2.8 (0.473) |
Final follow-up IOP | 15.6 ± 2.6/16.0 ± 2.8 (0.476) | 15.7 ± 2.7/16.2 ± 2.9 (0.450) | 15.4 ± 2.5/15.5 ± 2.6 (0.947) |
IOP spike number | 31/0 | 27/0 | 4/0 |
IOP elevation during spike (mmHg) | 7.1 ± 2.1 (6.0–16.6) | 7.0 ± 2.1 (6.0–16.6) | 7.7 ± 1.3 (6.3–9.4) |
RNFL thickness (μm) | |||
Month 6 | 108.1 ± 26.1/108.3 ± 24.2 (0.971) | 100.9 ± 12.1/102.1 ± 11.5 (0.656) | 135.4 ± 43.8/131.7 ± 41.9 (0.849) |
Final follow-up | 106.1 ± 19.4/107.0 ± 17.9 (0.821) | 100.6 ± 12.1/102.2 ± 11.9 (0.556) | 125.3 ± 27.4/123.5 ± 25.0 (0.872) |
